Facebook
Twitter
LinkedIn
Forward
Pitfalls, Perils and Pearls: Identifying and Managing Gynecologic Treatment Toxicity
The introduction of novel therapies for gynecologic malignancies such as immunotherapy, SBRT and complex brachytherapy can lead to increased frequency of severe toxicities for which treatment options may be limited. In absence of robust published data, clinicians may fail to recognize and appropriately manage these complications if they arise.
This educational activity is designed to raise awareness of the toxicities associated with gynecologic radiation therapy in the setting of advanced treatment modalities including complex interstitial or hybrid brachytherapy, immunotherapy and stereotactic ablative radiotherapy. We highlight the more severe or worrisome toxicities for which we have limited published data, but may arise more frequently as providers strive for durable local control in the setting of improved survival outcomes with immunotherapy. Our multidisciplinary panel of radiation oncologists, medical oncologist and a reconstructive urologist discuss the diagnosis and management of toxicities that include and are not limited to fistulas, cervical or vaginal necrosis, vaginal stenosis, immune-related colitis and radiation colitis. Additionally our speakers review the patient-specific and plan-specific risk factors which may predispose patients to treatment toxicity.
Topics:
- Immunotherapy Related Toxicity in the Setting of Pelvic Radiation and its Management
Ying Liu, MD, MPH - Complex Brachytherapy and Management of Toxicity for Advanced Gynecological Tumors
Supriya Chopra, MD - Surgical Management of Fistulas and Other Side Effects in an Irradiated Pelvis
Andrew Peterson, MD, MPH - Q and A
Full Panel
This activity is available from November 26, 2024, through 11:59 p.m. Eastern time on November 25, 2026.
This activity was originally recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists and surgeons.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify and initiate treatment for brachytherapy-related toxicity such as rectovaginal or vesicovaginal fistulas.
- Distinguish between immunotherapy-related versus radiation therapy induced colitis.
- Recognize risk factors which increase the probability of developing grade 3+ radiation toxicity.
- Dominique L. Rash, MD, is employed by the University of California, San Diego.
- Ying Liu, MD, MPH, is employed by Memorial Sloan Kettering Cancer Center. Dr. Liu receives grant/research funding from GSK, Artios Pharmaceuticals, Repare Therapeutics and AstraZeneca. Dr. Liu serves on the advisory board of Myriad Laboratories.
- Supriya Chopra, MD, is employed by ACTREC Tata Memorial Centre and Homi Bhabha National Institute. Dr. Chopra receives grant/research funding and honoraria from Varian and Elekta. Dr. Chopra serves in an advisory role with Merck Sharp Dohme and KORTUC Pharmaceuticals.
- Andrew Peterson, MD, MPH, is employed by Duke University Medical Center. Dr. Peterson receives grant/research funding and honoraria from Boston Scientific.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until November 25, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.